Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance
ConclusionsOur study demonstrates a substantial impact of the regulatory action to restrict use of SR in Europe: SR utilisation overall decreased strongly. The proportion of patients fulfilling the restricted indications, without contraindications, increased after the proposed RMMs.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
More News: Cardiology | Databases & Libraries | Denmark Health | European Medicines Agency (EMA) | Heart | Heart Disease | Hypertension | Italy Health | Netherlands Health | Orthopaedics | Osteoporosis | Primary Care | Spain Health | Study